After completion of the discovery phase of biomarker development (FP-0339) the verification phase will be initiated. The aim of the collaborative study FB-0259 is to confirm the newly detected marker candidates and newly developed methods in an independent clinical cross-sectional patient collective (Phase 2 of marker development) and to take them one step closer to application in medical practice. The collaborative study will investigate not only tissues, but also easily accessible body fluids such as whole blood, plasma, and saliva, which would later be used to measure biomarkers during clinical application. In order to expand and to mechanistically confirm the existing marker spectrum, proteins, epigenetic markers, and DNA markers (cancer-specific mutations and other aberrations), as well as RNA markers will be analyzed in plasma. After successful completion of the verification phase (Phase 2), the final biomarker validation will be carried out in a longitudinal study (Phase 3).
Lung tissue from 150 patients per year, in whom surgery for pulmonary carcinomas was performed, will be cryo-preserved. Whole blood, plasma, and saliva samples will be collected from the same patients. Tumor-free tissue from operated patients will also be collected. Furthermore, lymph node biopsies should be obtained from 50 additional patients.
-cross sectoral-Type of hazard:
occupational disease, carcinogenic substances, dust, fibers, particlesDescription, key words:
tumor markers, lung tumor